Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 242 de 371.

Grafa

Rockwell Medical achieves record gross margins and second consecutive year of adjusted EBITDA profitability

Rockwell Medical (NASDAQ:RMTI), a healthcare company focused on the manufacturing and distribution of life-sustaining hemodialysis products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Leia mais: Rockwell Medical achieves record gross margins and second consecutive year of adjusted EBITDA profitability
Grafa

Pony.ai, Uber, and Verne partner to launch Europe’s first commercial robotaxi service in Zagreb

Pony.ai (NASDAQ:PONY), a global leader in autonomous mobility, and Uber Technologies (NYSE:UBER) have announced a strategic partnership with the European service operator Verne to launch the first commercial robotaxi service in Europe.

Leia mais: Pony.ai, Uber, and Verne partner to launch Europe’s first commercial robotaxi service in Zagreb
Grafa

Ascentage Pharma reports 81% surge in Olverembatinib sales amid global Phase III expansion

Ascentage Pharma (NASDAQ:AAPG), a global biopharmaceutical company developing novel therapies for cancers, hepatitis B virus, and age-related diseases, announced its unaudited financial results for the year ended December 31, 2025.

Leia mais: Ascentage Pharma reports 81% surge in Olverembatinib sales amid global Phase III expansion
Grafa
Technology

Noah reports record operating income and 100% payout ratio following AI-driven transformation

Noah Holdings (NYSE:NOAH), a wealth management service provider for global Chinese high-net-worth investors, today announced financial results for the fourth quarter and full year ended December 31, 2025.

Leia mais: Noah reports record operating income and 100% payout ratio following AI-driven transformation
Grafa
Technology

PDD Holdings revenue growth moderates to 10% as heavy supply chain investments weigh on profits

PDD Holdings (NASDAQ:PDD) reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, revealing a narrative of steady top-line expansion tempered by the rising costs of its global ambitions.

Leia mais: PDD Holdings revenue growth moderates to 10% as heavy supply chain investments weigh on profits
Grafa

Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company pioneering the modulation of cortisol to treat severe disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant).

Leia mais: Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer
Grafa

Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm).

Leia mais: Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy
Grafa

Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.

Leia mais: Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028
Grafa

ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing

ProMIS Neurosciences (NASDAQ:PMN), a biotechnology company developing antibody therapeutics for neurodegenerative diseases, reported its full-year 2025 financial results and provided a comprehensive corporate update on March 25, 2026.

Leia mais: ProMIS Neurosciences advances Alzheimer’s pipeline following landmark $75.5M financing
Grafa

KalVista reports $49.1M in EKTERLY revenue as commercial pivot drives strategic transition

KalVista Pharmaceuticals (NASDAQ:KALV) today reported financial results for the abbreviated fiscal period ended December 31, 2025, marking the company’s formal transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity.

Leia mais: KalVista reports $49.1M in EKTERLY revenue as commercial pivot drives strategic transition